C-reactive protein levels and outcomes after statin therapy.

By P. Ridker, C. Cannon, D. A. Morrow, N. Rifai, L. Rose, C. Mccabe, M. Pfeffer, E. Braunwald. New England Journal of Medicine, 2005

2,304 citations recorded by the source corpus.

Subfields: Cancer Research, Epidemiology, Surgery

View Paper: https://www.semanticscholar.org/paper/5b186934650717f819203316cda51db6f6f0efca

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Peter Libby
2. G. Hansson
3. Børge G. Nordestgaard
4. Ralph Weissleder
5. M. Pittet
6. P. Ridker

In Epidemiology

1. Peter Libby
2. P. Ridker
3. G. Hansson
4. V. Z. Rocha
5. Børge G. Nordestgaard
6. T. Thuren
7. J. Willerson
8. A. Zalewski

In Surgery

1. Peter Libby
2. P. Ridker
3. G. Hansson
4. V. Z. Rocha
5. T. Thuren
6. A. Zalewski
7. J. Willerson
8. Børge G. Nordestgaard

Citations in the corpus

• Inflammation and cardiovascular disease mechanisms. (2006, background): “A recent paper reported exactly that: in patients with acute coronary syndrome undergoing statin therapy, individuals with CRP concentrations 2 mg/L showed a lower risk of recurrent MI or death from cardiovascular causes thandidthosewithhigherconcentrations(2.8comparedwith3.9 events per 100 person-y”
• Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. (2010, background): “Furthermore, studies showing that therapies that reduce inflammation may improve cardiovascular outcome also support the role of inflammation (Ridker et al., 2005).”
• C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. (2007, neutral): “…analysis addressing whether best clinical outcomes were obtained among acute coronary syndrome patients treated with statins who had LDL cholesterol reduced below 70 mg/dl or who had hsCRP levels reduced below 2 mg/l, the approximate median values for both variables after 30 days of therapy (77).”
• Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. (2007, background): “In contrast, since inhibitors of hydroxymethylglutaryl coenzyme A reductase (statins) decrease cholesterol levels, exert antiinflammatory effects, and attenuate atherosclerosis (36, 37), we sought to determine whether concurrent treatment of apoE–/– mice on Western diet with statin also modulates th”